Trademark Overview
On Friday, August 23, 2024, a trademark application was filed for CPTX with the United States Patent and Trademark Office. The USPTO has given the CPTX trademark a serial number of 98714397. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Thursday, September 11, 2025. This trademark is owned by CPTx GmbH. The CPTX trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical preparations, namely, DNA, synthetic DNA and single-strand DNA for use in the fields of gene therapy, gene editing, cell therapy, cancer therapy, virus production, DNA-vaccination, gene transfer, immunotherapy, antivirals, and synthetic DNA nanostructures for the purpose of delivering drugs and therapies; medicines comprised of DNA for gene therapy, gene editing, cell therapy, cancer therapy, virus production, DNA-vaccination, gene transfer, immunotherapy, antivirals, and synthetic DNA nanostructures for the purpose of delivering drugs and therapies; diagnostic preparations comprising nucleotide sequences for medical and veterinary purposes
Medical and pharmaceutical services in the field of DNA, namely, medical analysis of DNA for the diagnosis and treatment of persons, DNA screening for medical purposes, genetic testing for medical purposes
Scientific and technological services, namely scientific research and analysis in the field of DNA; biochemical and biotechnological services, namely research and development of custom-specific DNA; research services in the field of DNA, namely, analysis for scientific research purposes and repair technology, mutation and sequencing; biochemical and biotechnological services, namely protein design and development; testing of new products for third parties; scientific DNA screening for scientific research purposes for third parties; protein screening for scientific research purposes for third parties; industrial DNA screening to ensure biopharmaceutical purity and to detect and identify pathogens for third parties for the purposes of scientific and biotechnological research and development; industrial protein screening to ensure biopharmaceutical purity and to detect and identify pathogens for third parties for the purposes of scientific and biotechnological research and development
